Latest other current liabilities for MACK: $23M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Merrimack Pharmaceuticals (MACK) currently reports a other current liabilities of $23M as of March 2024. That compares with $370K in the prior-year period — up 5917.1% year over year. Use the charts on this page to explore Merrimack Pharmaceuticals's other current liabilities history and peer comparisons.
Merrimack Pharmaceuticals's other current liabilities increased from $370K to $23M — a 5917.1% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Merrimack Pharmaceuticals reported $23M in other current liabilities as of March 2024. That compares with $370K in the prior-year period — up 5917.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current other current liabilities of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Merrimack Pharmaceuticals, and consider following MACK for alerts when major investors trade the stock.
Merrimack Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MACK with unrelated industries.